



01-16-04

CASE PH 7269 DIV 1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10EV305489796US
Express Mail Label NumberJanuary 15, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBERT CHERNEY

APPLICATION NO:

FILED:

FOR: CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE
RECEPTOR ACTIVITY

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/027644 filed December 20, 2001, and copies are available therein. However, applicant is willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4379

Date: January 15, 2004

Please type a plus sign (+) inside this box

→ +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/706,448
Filing Date	November 12, 2003
First Named Inventor	Cherney, Robert
Group Art Unit	
Examiner Name	
Attorney Docket Number	PH-7269 DIV 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,851,423		Girijavallabhan et al.	07/25/1989	
		5,272,167		Girijavallabhan et al.	12/21/1993	
		5,710,171		Dinsmore et al.	01/20/1998	
		5,770,620		Mjalli et al.	06/23/1998	
		5,968,965		Dinsmore et al.	10/19/1999	
		5,981,491		Baxter et al.	11/09/1999	
		6,011,052		Padia et al.	01/04/2000	
		6,028,087		Bondinell et al.	02/22/2000	
		6,030,946		Klaus et al.	02/29/2000	
		6,048,861		Askew et al.	04/11/2000	
		6,084,065		Cammaggi et al.	07/04/2000	
		6,100,423		Collins et al.	08/08/2000	
		6,162,790		Bemis et al.	12/19/2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			93/15047		WIPO	08/05/1993		
			94/03479		WIPO	02/17/1994		
			94/20062		WIPO	09/15/1994		
			96/22966		WIPO	08/01/1996		
			97/00894		WIPO	01/09/1997		
			97/44329		WIPO	11/27/1999		
			98/06703		WIPO	02/19/1998		
			99/07351		WIPO	02/18/1999		
			99/07678		WIPO	02/18/1999		
			99/17790		WIPO	04/15/1999		
			99/25686		WIPO	05/27/1999		
			99/40913		WIPO	08/19/1999		
			99/40914		WIPO	08/19/1999		
			00/42071		WIPO	07/20/2000		
			00/46196		WIPO	08/10/2000		
			00/69815		WIPO	11/23/2000		
			00/69820		WIPO	11/23/2000		
			0264795		EUROPE	10/13/1987		
			0731107		EUROPE	02/10/1996		
			0560407		EUROPE	12/09/1987		
			377869		JAPAN	03/04/1991		
			00/76512		WIPO	12/21/2000		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hr Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet


2

of

2

Complete if Known

Application Number	10/706,448
Filing Date	November 12, 2003
First Named Inventor	Cherney, Robert
Group Art Unit	
Examiner Name	
Attorney Docket Number	PH-7269 DIV 1

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BABA et al., A Small-Molecule, Nonpeptide CCR5 Antagonist With Hihgly Potent and Selective Anti-HIV-1 Activity, Proc. Natl. Acad. Sci., May 1999, Volume 96, pp. 5698-5703.	
		FORBES, et al., CCR2B Receptor Antagonists: Conversion of a Weak HTS it to a Potent Lead Compound, Bioorganic and Medicinal Chemistry Letters, 2000, Volume 10, pp. 1803-1806.	
		MIRZADEGAN, et al. Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists, The Journal of Biological Chemistry, 2000, Volume 275 No. 33, pp. 25562-25571.	

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

